Jessica Sachs

1.7k total citations
23 papers, 790 citations indexed

About

Jessica Sachs is a scholar working on Immunology, Oncology and Hematology. According to data from OpenAlex, Jessica Sachs has authored 23 papers receiving a total of 790 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 9 papers in Oncology and 6 papers in Hematology. Recurrent topics in Jessica Sachs's work include CAR-T cell therapy research (9 papers), Mast cells and histamine (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Jessica Sachs is often cited by papers focused on CAR-T cell therapy research (9 papers), Mast cells and histamine (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). Jessica Sachs collaborates with scholars based in United States, United Kingdom and Germany. Jessica Sachs's co-authors include Mary Custer, Timothy M. Clay, Patrick Hwu, Michael I. Nishimura, Steven A. Rosenberg, Guiling Zhao, Yong‐Guang Yang, Denise A. Pearson, Megan Sykes and Kirsten Swenson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

Jessica Sachs

23 papers receiving 783 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jessica Sachs United States 9 497 442 206 162 112 23 790
Bartosz Grzywacz United States 14 960 1.9× 597 1.4× 266 1.3× 38 0.2× 204 1.8× 31 1.2k
D. Huhn Germany 13 366 0.7× 398 0.9× 184 0.9× 65 0.4× 156 1.4× 25 765
Rachel Koldej Australia 17 162 0.3× 247 0.6× 158 0.8× 148 0.9× 293 2.6× 59 771
Mireya Paulina Velasquez United States 15 271 0.5× 589 1.3× 156 0.8× 156 1.0× 218 1.9× 42 783
G Risdon United States 11 394 0.8× 216 0.5× 388 1.9× 86 0.5× 137 1.2× 14 843
Jeffrey J. Pu United States 14 269 0.5× 241 0.5× 143 0.7× 54 0.3× 214 1.9× 50 686
Mingqing Zhu China 11 380 0.8× 439 1.0× 278 1.3× 101 0.6× 246 2.2× 53 809
Margit Schmidt Germany 7 384 0.8× 715 1.6× 153 0.7× 66 0.4× 232 2.1× 13 1.0k
Stern Ac Netherlands 10 210 0.4× 438 1.0× 590 2.9× 113 0.7× 90 0.8× 11 858
Alyssa Johnsen United States 13 524 1.1× 160 0.4× 159 0.8× 41 0.3× 168 1.5× 25 907

Countries citing papers authored by Jessica Sachs

Since Specialization
Citations

This map shows the geographic impact of Jessica Sachs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jessica Sachs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jessica Sachs more than expected).

Fields of papers citing papers by Jessica Sachs

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jessica Sachs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jessica Sachs. The network helps show where Jessica Sachs may publish in the future.

Co-authorship network of co-authors of Jessica Sachs

This figure shows the co-authorship network connecting the top 25 collaborators of Jessica Sachs. A scholar is included among the top collaborators of Jessica Sachs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jessica Sachs. Jessica Sachs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Muñoz, Javier, Ian W. Flinn, Jonathon B. Cohen, et al.. (2023). Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma. Transplantation and Cellular Therapy. 30(2). 241.e1–241.e8. 2 indexed citations
2.
Tap, William D., Andrew J. Wagner, Sebastian Bauer, et al.. (2023). Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study.. Journal of Clinical Oncology. 41(16_suppl). 11537–11537. 5 indexed citations
3.
DeAngelo, Daniel J., Vinod Pullarkat, Miguel Piris‐Villaespesa, et al.. (2022). Preliminary Safety and Efficacy from Apex, a Phase 2 Study of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Adults with Advanced Systemic Mastocytosis (AdvSM). Blood. 140(Supplement 1). 1512–1513. 12 indexed citations
4.
Akin, Cem, Frank Siebenhaar, Michael W. Deininger, et al.. (2022). Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM). Blood. 140(Supplement 1). 6838–6839. 7 indexed citations
5.
Guarnieri, Anna L., Mark J. Chicarelli, Karyn Bouhana, et al.. (2021). Preclinical Data with KIT D816V Inhibitor Bezuclastinib (CGT9486) Demonstrates High Selectivity and Minimal Brain Penetrance. Blood. 138(Supplement 1). 4595–4595. 8 indexed citations
6.
Gotlib, Jason, Tracy I. George, Michael W. Deininger, et al.. (2021). A Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Advanced Systemic Mastocytosis (AdvSM). Blood. 138(Supplement 1). 3636–3636. 6 indexed citations
7.
Flinn, Ian W., Jason R. Westin, Jonathon B. Cohen, et al.. (2019). Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin Lymphoma. Blood. 134(Supplement_1). 1587–1587. 1 indexed citations
8.
9.
Locatelli, Franco, Christine Mauz‐Koerholz, Kathleen Neville, et al.. (2018). Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. The Lancet Haematology. 5(10). e450–e461. 65 indexed citations
10.
O’Callaghan, Katie, Allison Nelson, Greg Motz, et al.. (2017). Adaptability of Antibody-Coupled T Cell Receptor (ACTR) Engineered Autologous T Cells in Combination with Daratumumab over CAR-Based Approaches. Blood. 130. 3189–3189. 2 indexed citations
11.
Locatelli, Franco, Christine Mauz‐Koerholz, Kathleen Neville, et al.. (2017). A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R) SYSTEMIC ANAPLASTIC LARGE‐CELL LYMPHOMA (SALCL) OR R/R HODGKIN LYMPHOMA (HL). Hematological Oncology. 35(S2). 248–249. 4 indexed citations
12.
13.
14.
Li, Hao Wei, et al.. (2012). Nonalloreactive T Cells Prevent Donor Lymphocyte Infusion–Induced Graft-versus-Host Disease by Controlling Microbial Stimuli. The Journal of Immunology. 189(12). 5572–5581. 12 indexed citations
15.
Pai, Sung‐Yun, Ofer Levy, Haifa H. Jabara, et al.. (2008). Allogeneic transplantation successfully corrects immune defects, but not susceptibility to colitis, in a patient with nuclear factor-κB essential modulator deficiency. Journal of Allergy and Clinical Immunology. 122(6). 1113–1118.e1. 30 indexed citations
16.
Saad, Ali G., Jessica Sachs, Christopher D. Turner, et al.. (2007). Extracranial Metastases of Glioblastoma in a Child. Journal of Pediatric Hematology/Oncology. 29(3). 190–194. 34 indexed citations
17.
Sachs, Jessica & Megan Sykes. (2007). Lymphopenia Promotes the Development of Graft-Versus-Host Disease upon Donor Leukocyte Infusion.. Blood. 110(11). 2185–2185. 1 indexed citations
18.
Chakraverty, Ronjon, Hyeon‐Seok Eom, Jessica Sachs, et al.. (2006). Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood. 108(6). 2106–2113. 79 indexed citations
19.
Pearson, Denise A., Kirsten Swenson, Guiling Zhao, et al.. (1999). Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biology of Blood and Marrow Transplantation. 5(3). 133–143. 151 indexed citations
20.
Clay, Timothy M., Mary Custer, Jessica Sachs, et al.. (1999). Efficient Transfer of a Tumor Antigen-Reactive TCR to Human Peripheral Blood Lymphocytes Confers Anti-Tumor Reactivity. The Journal of Immunology. 163(1). 507–513. 335 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bartosz Grzywacz Breakdown of academic impact, for papers by D. Huhn Breakdown of academic impact, for papers by Rachel Koldej Breakdown of academic impact, for papers by Mireya Paulina Velasquez Breakdown of academic impact, for papers by G Risdon Breakdown of academic impact, for papers by Jeffrey J. Pu Breakdown of academic impact, for papers by Mingqing Zhu Breakdown of academic impact, for papers by Margit Schmidt Breakdown of academic impact, for papers by Stern Ac Breakdown of academic impact, for papers by Alyssa Johnsen
Rankless by CCL
2026